CGTX (Cognition Therapeutics) Short-Term Capital Lease Obligation : $0.19 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Cognition Therapeutics Short-Term Capital Lease Obligation?

Cognition Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.19 Mil.

Cognition Therapeutics's quarterly Short-Term Capital Lease Obligation increased from Mar. 2024 ($0.18 Mil) to Jun. 2024 ($0.18 Mil) and increased from Jun. 2024 ($0.18 Mil) to Sep. 2024 ($0.19 Mil).

Cognition Therapeutics's annual Short-Term Capital Lease Obligation increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.15 Mil) and increased from Dec. 2022 ($0.15 Mil) to Dec. 2023 ($0.17 Mil).

Cognition Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Cognition Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cognition Therapeutics Short-Term Capital Lease Obligation Chart

Cognition Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

0.15

0.17

Cognition Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.17	0.17	0.18	0.18	0.19

Cognition Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Cognition Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Cognition Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Cognition Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cognition Therapeutics Inc (NAS:CGTX) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

2500 Westchester Avenue, Purchase, NY, USA, 10577

Website

https://www.cogrx.com

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Executives

Lisa Ricciardi	director, officer: CEO & President	C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
John Brendan Doyle	officer: Chief Financial Officer	C/O CHIASMA INC., 140 KENDRICK STREET BUILDING C EAST, NEEDHAM MA 20494
Anthony Caggiano	officer: Chief Medical Officer	C/O COGNITION THERAPEUTICS, INC., 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Ellen B Richstone	director	C/O SONUS NETWORKS, INC., 7 TECHNOLOGY PARK DRIVE, WESTFORD MA 01886
Fletcher Aaron G.l.	director	40 GUEST STREET, BOSTON MA 02135
Leslie W. Kreis	director, 10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Memory Spv Ii, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Equity Partners Ii, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Qp, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Peggy Wallace	director	C/O COGNITION THERAPEUTICS, INC., 2500 WESTCHESTER AVE., PURCHASE NY 10577
Bios Equity Partners Iii, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Ii Nt, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107